Bellerophon Therapeutics, Inc. (BLPH) |
|
0.9 -0.043 (-4.56%)
|
06-06 16:00 |
|
Open: |
0.9163 |
Pre. Close: |
0.943 |
|
High:
|
1.04 |
Low:
|
0.8769 |
|
Volume:
|
3,347,491 |
Market Cap:
|
9(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 3:48:03 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 8.43  One year: 13.02 |
| Support: |
Support1: 0.87 Support2: 0.72 |
| Resistance: |
Resistance1: 7.22 Resistance2: 11.14 |
| Pivot: |
6.99 |
| Moving Average: |
MA(5): 4.54 MA(20): 7.43
MA(100): 5.89 MA(250): 3.07 |
| MACD: |
MACD(12,26): -1.4 Signal(9): -0.6 |
| Stochastic oscillator: |
%K(14,3): 3.6 %D(3): 5.6 |
| RSI: |
RSI(14): 19.7 |
| 52-week: |
High: 12.57 Low: 0.67 |
| Average Vol(K): |
3-Month: 478 (K) 10-Days: 1,655 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BLPH ] has closed below the lower bollinger band by 7.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 176.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.34 - 1.35 |
1.35 - 1.36 |
|
Low:
|
0.87 - 0.88 |
0.88 - 0.89 |
|
Close:
|
0.93 - 0.94 |
0.94 - 0.95 |
|
Company Description |
|
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. |
Headline News |
Tue, 06 Jun 2023
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails - Nasdaq
Tue, 06 Jun 2023
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails - Yahoo Finance
Mon, 05 Jun 2023
Dow Drops Over 100 Points; Crude Oil Rises - Chemours (NYSE:CC), Bellerophon Therapeutics (NASDAQ:BLPH) - Benzinga
Mon, 05 Jun 2023
Healthcare Stocks on the Move Monday: TMBR, MGRX, SCLX, ABEO, BLPH, CSTL, MNK, PDSB - InvestorsObserver
Mon, 05 Jun 2023
Nasdaq Rises 70 Points; ISM Services PMI Drops In May - Bellerophon Therapeutics (NASDAQ:BLPH), Circor In - Benzinga
Mon, 05 Jun 2023
US Stocks Mixed; SAIC Posts Upbeat Results - Bellerophon Therapeutics (NASDAQ:BLPH), Aemetis (NASDAQ:AMTX - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
10 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
4.1 (%) |
|
% Held by Institutions
|
44.4 (%) |
|
Shares Short
|
240 (K) |
|
Shares Short P.Month
|
435 (K) |
Stock Financials |
|
EPS
|
-1.2 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1 |
|
Profit Margin (%)
|
-201.6 |
|
Operating Margin (%)
|
-270.8 |
|
Return on Assets (ttm)
|
-50.7 |
|
Return on Equity (ttm)
|
-85 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.53 |
|
EBITDA (p.s.)
|
-1.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-10 (M) |
|
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
|
PE Ratio
|
-0.77 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.89 |
|
Price to Sales
|
1.67 |
|
Price to Cash Flow
|
-0.97 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
